Latest food-allergy stories and video coverage scraped from trusted sources — including SnackSafely.com, Allergic Living, the Harvard Nadeau Lab, NIAID, and broadcast & new-media reports from news stations nationwide. Content is verified and linked to the original source.
Items are compiled via live web search from real news outlets and trusted food-allergy sources, then stored in our database. Headlines and links point to the original articles or video pages — always verify details by reading the full source. This feed is for awareness only and is not medical advice.
The report highlights nationwide statutory updates modernizing school stock epinephrine legislation from auto-injectors to broader device-neutral language like 'epinephrine delivery systems'. This shift allows schools in states across the country to stock newly approved needle-free alternatives, such as epinephrine nasal sprays.
The FDA approved Xolair (omalizumab) injection to reduce allergic reactions caused by accidental exposure in individuals aged 1 year and older with IgE-mediated food allergies. The historic approval offers multi-allergic families a preventive medication to mitigate severe outcomes like anaphylaxis. Clinical trial results verified that treated patients tolerated substantially higher amounts of key allergens such as peanut, milk, and egg.
Researchers at Massachusetts General Hospital have updated and refined clinical criteria to more reliably detect anaphylactic episodes in infants and toddlers. Diagnosing anaphylaxis in non-verbal children remains challenging due to atypical or subtle symptoms. The improved framework helps pediatricians and caregivers administer prompt, life-saving epinephrine treatment.
California Governor Gavin Newsom signed California's Elijah's Law into effect on September 25, 2024. The legislation mandates three state agencies to establish comprehensive anaphylaxis policies and emergency protocols for child care facilities.
Advocacy organizations across the nation are working to update existing state stock epinephrine statutes to modern 'epinephrine delivery device' language. The policy updates ensure school districts can legally stock needle-free epinephrine alternatives like nasal sprays.
SnackSafely reported on emerging diagnostic advancements aimed at improving the accuracy of food allergy testing via specialized blood sampling. The new testing methodologies aim to minimize reliance on high-risk oral food challenges. This development offers families and clinicians safer tools to confirm food sensitivities.
NIAID outlined its ongoing strategic priority to research food allergies due to their rising prevalence and public health impact among children and adults. The agency detailed research tracks into risk factors, the nutritional strain of avoiding ubiquitous allergens, and underlying immune triggers. It highlights federal efforts to advance preventative strategies and innovative therapies.
Following the enactment of childcare allergy protections in Maryland, advocates reported building momentum for Elijah's Law legislation in Missouri. The Elijah-Alavi Foundation noted active collaboration with Missouri state representatives, including Emily Weber and Anthony Ealy, to advance and amend childcare anaphylaxis safety protocols.
Efforts are accelerating to pass federal legislation known as the ADINA Act to require clear allergen transparency on medication labels. The bill seeks to protect individuals with severe food and ingredient allergies from hidden excipients in prescription and over-the-counter drugs.
Researchers at the University of Bern have developed a new diagnostic test designed to improve accuracy when detecting food allergies. Data showed significantly higher diagnostic accuracy compared to standard skin tests and specific IgE antibody blood measurements.
Research funded by the National Institutes of Health has revealed new insights into how the human digestive and immune systems differentiate between harmless food nutrients and potential allergens. The discoveries provide potential mechanisms for future preventative strategies and therapies.
An analysis evaluates ongoing research at Clemson University aimed at engineering genetically modified, reduced-allergen peanuts. The piece questions whether reducing allergenicity provides true safety for consumers with life-threatening allergies or risks creating a false sense of security.
New York City advanced legislation to require stock epinephrine in schools and childcare facilities, alongside trained personnel on-site. Advocates are also championing state bill S8587 to strengthen Elijah's Law statewide by requiring daycare stock epinephrine and incident tracking.
In detailing advocacy milestones around stock epinephrine and childcare allergy protections, the report highlights that Elijah's Law has passed locally in Kansas City, Missouri. It also notes ongoing efforts by advocates to reintroduce and enact statewide childcare allergy safety mandates in Missouri's legislature.
A large epidemiological review evaluating over 120,000 children across dozens of US pediatric clinics documented a 36 percent decline in overall early-childhood food allergies between 2012 and 2020. The decrease was largely attributed to a 43 percent drop in diagnosed peanut allergies following the adoption of infant dietary introduction guidelines. Researchers noted that egg has now overtaken peanut as the leading diagnosed food allergy in children under age three.
In a Phase 2a clinical trial evaluating the investigational monoclonal antibody TEV ’408, researchers found that a single injection significantly protected patient intestinal lining during six weeks of daily gluten challenge. Treated patients also exhibited a dramatic reduction in inflammatory intraepithelial lymphocytes and lower gastrointestinal symptom scores compared to placebo. The study provides proof of concept for the first potential non-dietary therapeutic candidate to reduce gluten-induced damage.
Harvard Chan School spotlighted Dr. Kari Nadeau's appearance on CNN discussing a major clinical trial examining early preventative therapies in 800 infants with allergic skin conditions. The seven-year trial, which monitors high-risk babies to intercept food allergy pathways early, faced severe operational risks following federal research funding disruptions. Dr. Nadeau emphasized that abrupt pauses to clinical trials endanger pediatric patient safety and stall crucial preventative medicine.
The FDA approved Xolair (omalizumab) injection for reducing allergic reactions, including anaphylaxis, caused by accidental exposure in people with multiple food allergies. Approval was supported by data from the Phase III OUtMATCH study funded by NIAID.
SnackSafely released comprehensive updates to its Safe Snack Guide catalog to support families and schools managing food allergies. The updated guide details allergen-safe products across multiple major allergens to prevent cross-contact in classrooms.
A family has initiated legal action against an airline following the tragic death of a teenager who suffered a fatal allergic reaction to a sandwich served during a flight. The lawsuit highlights critical gaps in airline allergen labeling and emergency response protocols.
A study tracking over 1,300 children found that multi-food allergy is highly prevalent, suggesting that traditional single-allergy testing may be insufficient. The findings support more targeted screening to better manage complex pediatric health profiles.
The FDA has granted Fast Track designation to a new, next-generation therapy aimed at treating peanut allergies, potentially accelerating its development and review process.
New research indicates that biological markers associated with persistent food allergies may be detectable in the placenta at the time of birth.
As the school year begins, experts emphasize the critical importance of updating emergency action plans for students with food allergies to ensure school staff are prepared for potential reactions.
New York lawmakers are advancing legislation to mandate access to stock epinephrine in childcare settings and require staff training to protect young children with food allergies.
This update highlights the results of the OUtMATCH clinical trial, led by researchers including Dr. Kari Nadeau, which demonstrated that omalizumab (Xolair) significantly increased the threshold of tolerance for multiple food allergens. The study provided the primary evidence for the subsequent FDA approval of the drug for food allergy management.
This report details the landmark approval of the needle-free emergency treatment Neffy, highlighting its portability and potential to reduce "needle phobia" barriers. The article includes commentary from medical experts on how the 2mg nasal dose compares to traditional auto-injectors.
The NIAID released a formal statement regarding the FDA’s decision to approve Xolair for food allergies based on NIH-funded research. The drug is the first approved medication to reduce allergic reactions to multiple foods following accidental exposure in patients aged 1 year and older.
Experts warn of the rise of AI-generated misinformation regarding food allergy 'cures' circulating on social media. Organizations like Food Allergy Canada are actively debunking these false claims to protect the community.
A large-scale study involving 2.8 million children has identified significant risk factors associated with the development of food allergies. The findings provide new insights into early-life predictors for allergic conditions.
The Protecting Children with Food Allergies Act mandates specialized training for school food service personnel to better recognize and respond to allergic reactions. The law aims to improve safety for students with undiagnosed or known food allergies.
A large-scale study involving 2.8 million children has identified significant risk factors associated with the development of food allergies. The findings aim to help researchers and families better understand the origins of these conditions.
Advocates are expressing strong opposition to a proposed FAA rule that would allow airlines to choose whether or not to stock epinephrine devices on flights. The community argues this could compromise passenger safety.
California enacted Elijah's Law, which mandates anaphylaxis policies in licensed childcare facilities. The law allows facilities to opt into these safety protocols starting January 1, 2028.
This feature marks the one-year anniversary of the first needle-free epinephrine treatment, examining its impact on patient compliance and emergency preparedness. Experts from the AAFA and Cleveland Clinic discuss how the availability of a nasal spray has reduced the "needle phobia" barrier in schools and public spaces.
The Nadeau Lab reports on the precarious status of longitudinal studies like Project Viva due to shifts in federal research funding. These studies are critical for understanding how environmental factors and early-life exposures contribute to the development of IgE-mediated food allergies.
Long-term data from the EPITOPE extension study shows that the investigational peanut patch continues to build tolerance over time. After three years of daily wear, a majority of participants could safely tolerate a significant accidental ingestion, marking a major milestone for epicutaneous immunotherapy (EPIT).
Researchers have launched a new clinical trial for the Viaskin Peanut patch specifically for infants aged 6 to 12 months. The study aims to leverage the "plasticity" of the infant immune system to induce long-term tolerance, potentially allowing for unrestricted peanut consumption later in life.
A high-level FDA roundtable explored the "modern epidemic" of food allergies, focusing on shifting medical guidance from avoidance to early introduction. The panel highlighted that approximately 80,000 new peanut allergy cases were diagnosed in 2024 alone, emphasizing the need for standardizing infant feeding protocols.
Delaware passed House Bill 95, making it the second state to require insurance plans to cover epinephrine auto-injectors for children and teens, significantly improving affordability for families.
President Trump signed the bipartisan Protecting Children with Food Allergies Act into law, mandating allergy training for school food personnel. The legislation is designed to ensure staff can effectively recognize and respond to allergic reactions in school settings.
Researchers have identified a link between specific gut microbiome compositions and the development of FPIES, a non-IgE-mediated food allergy. The study suggests that early gut health may play a critical role in the manifestation of these allergies.
FARE released the Food Allergy Management in Schools (FAMS) report, providing updated recommendations for staff training, emergency preparedness, and allergen prevention. The guidance aims to enhance existing CDC protocols to better protect students with food allergies.
Researchers from Charité–Universitätsmedizin Berlin developed machine learning models that predict oral food challenge (OFC) outcomes for peanut allergy with up to 96% accuracy, according to a study published in the Journal of Allergy and Clinical Immunology: Global. Analyzing data from 96 peanut-sensitized individuals, the combined clinical-plus-basophil activation test (BAT) model achieved 96% accuracy, while a clinical-only model reached 95% — potentially offering a safer, less resource-intensive alternative to in-clinic food challenges.
New York state enacted a price cap law that eliminates out-of-pocket costs for asthma inhalers for residents, improving access to essential respiratory medication.
New York is expanding the scope of Elijah's Law, which originally focused on food allergy policies in childcare, to now include requirements for stock epinephrine and staff training.
A new microneedle patch technology designed to treat peanut allergies has successfully progressed into its first human clinical trial phase.
A teenager who experienced severe allergic reactions has developed a new resource to help improve food allergy safety and awareness within school environments.
FARE released the Food Allergy Management in Schools (FAMS) report, providing updated recommendations for staff training, epinephrine access, and emergency preparedness in schools.
Virginia has implemented new legislation aimed at improving allergen and gluten labeling for takeout food, serving as a potential model for other states.
Recent research highlights that a significant majority of children with food allergies are allergic to more than one food, emphasizing the need for comprehensive screening.
A legal case involving a teenager who suffered a fatal allergic reaction to an airline meal has prompted renewed calls for better allergen safety and training on commercial flights.
This article discusses the shift in food allergy management from strict avoidance to novel therapies. It highlights breakthroughs in immunology and biotechnology aimed at achieving long-term remission.
The Nadeau Lab provides updates on the Stopping Eczema and Allergy (SEAL) trial and research into using biologics to improve the safety and efficacy of oral immunotherapy for food allergies.
Research supported by the NIAID indicates that omalizumab is more effective than traditional oral immunotherapy for treating multiple food allergies. The study highlights advancements in therapeutic options for patients at risk of severe allergic reactions.
The National Institute of Allergy and Infectious Diseases (NIAID) highlights the approval of omalizumab for multi-food allergy treatment following the successful OUtMATCH clinical trial. The study demonstrated that a significant majority of participants could consume small amounts of peanut, milk, egg, and cashew without a systemic reaction after treatment.
Xolair (omalizumab) has received FDA approval for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods. The drug is intended for adults and children aged 1 year and older to increase their tolerance threshold.
The FDA has officially approved Neffy, an epinephrine nasal spray developed by ARS Pharmaceuticals for the emergency treatment of Type I allergic reactions, including anaphylaxis. This marks the first time a non-injectable treatment option has been made available for food-allergic patients.
Researchers at the Karolinska Institutet published a study in The Lancet Regional Health – Europe showing promising results for peanut oral immunotherapy in children aged 1–3 years. The study highlights the potential for early intervention during a period when the immune system is highly adaptable.
New York City implemented a mandate requiring schools and daycares to stock epinephrine, serving as a potential precedent for other states and municipalities to follow.
Governor Kathy Hochul signed a new law requiring insurers to provide both maintenance and rescue inhalers to patients at no cost. The legislation, introduced by Assemblymember Jessica González-Rojas, aims to ensure affordability for over a million New Yorkers.
Following a fatal allergic reaction, the parents of a Texas student are advocating for mandatory ingredient transparency in restaurant menus. The article discusses the ongoing struggle for safer dining practices for the food-allergic community.
The Nadeau Lab provides updates on the Stopping Eczema and Allergy (SEAL) trial, a Phase II clinical study investigating the genetic and environmental factors that lead to food allergies. The report highlights the role of the filaggrin gene mutation in allergy development.
A recent review highlights that food allergies are frequently underdiagnosed or overlooked in the aging population, leading to potential health risks. The article emphasizes the need for increased awareness among healthcare providers regarding adult-onset allergies.
SnackSafely.com announced nine new manufacturing partners for its allergen transparency program. These companies provide detailed information on shared lines and facility practices to help consumers make safer food choices.
SnackSafely.com introduced a new service featuring digital badges to help consumers identify allergen-safe products at the point of sale. The initiative aims to eliminate guesswork for families managing severe food allergies.
New research indicates that casual skin contact with food allergens, such as touching a surface, carries an extremely low risk of triggering a severe allergic reaction. This finding helps clarify safety protocols for schools and public spaces.
A recent review highlights that food allergies are frequently underdiagnosed or overlooked in the aging population. The article emphasizes the need for increased clinical awareness of allergic symptoms in older adults.
California became the fifth state to enact Elijah's Law, which mandates emergency protocols, staff training, and epinephrine access in childcare facilities to protect children with food allergies.
This editorial discusses the implications of a recent food recall, highlighting ongoing concerns regarding the reliability of food labeling and the responsibility of large manufacturers toward the allergic community.
Advocates are actively pushing for the passage of Elijah's Law in Pennsylvania to mandate food allergy safety protocols in childcare facilities.
This article highlights the advocacy efforts to expand 'Elijah's Law'—which mandates allergy safety protocols in daycares—to states including New Jersey.
An FDA roundtable discussed the "modern epidemic" of food allergies affecting over 33 million Americans, focusing on prevention through early infant feeding. The panel emphasized that even infants with mild eczema should be introduced to allergens early to maximize prevention rates.
Following the FDA approval of Xolair (omalizumab) for food allergies, several pharmaceutical companies are seeking approval for biosimilars to increase competition and lower costs. The FDA approved the first biosimilar, Omlyclo, in March 2025, with a commercial launch expected by late 2026.
Long-term follow-up from the LEAP trial confirms that introducing peanut products to infants between 4 and 11 months old reduces the risk of peanut allergy in adolescence by 71%. The study proves that early introduction confers lasting protection, even if peanut consumption becomes irregular later in childhood.
Researchers at Boston Children’s Hospital are moving into Phase 2 of a study using fecal microbial transplantation (MTT) capsules to treat peanut allergy. The goal is to reshape the gut microbiome of allergic patients with microbes from healthy donors to induce immune tolerance.
A new study indicates that casual skin contact with common food allergens like peanuts or milk is unlikely to trigger a systemic allergic reaction. The findings aim to reduce anxiety for families managing severe food allergies in public spaces.
While we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.
